臨床試驗

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

NCT：NCT03686124 · RECRUITING

NCT IDNCT03686124

狀態RECRUITING

開始日期2019-05-14

SponsorImmatics US, Inc. (INDUSTRY)

First posted2018-09-26

Last updated2026-05-13

簡要摘要

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。